CHOOSING HUMALOG®

Adding mealtime insulin to diabetes therapy

Consider Humalog for your patients with type 2 diabetes

Do you have a patient with type 2 diabetes who...

  • Needs rapid-acting insulin, in addition to long-acting insulin, to manage postmeal glucose levels?
  • Is willing to add mealtime insulin injections to current basal insulin injections?
  • Has long partnered well with you and kept to your treatment plan?
  • Is ready to start mealtime insulin?
  • Wants an insulin regimen that allows flexibility around family meals?

Consider Humalog

Dosage of Humalog must be individualized. Humalog given by subcutaneous injection should generally be used in regimens with intermediate- or long-acting insulins.

Learn more about Humalog Learn about Humalog U-100 self-titration dosing Learn more about the efficacy of Humalog

With Humalog U-200 KwikPen, patients can have a mealtime insulin pen that lasts longer between pen changes*

Consider Humalog U-200 KwikPen

  • Is bioequivalent to Humalog U-100; therefore, you should expect similar efficacy as Humalog U-1001
  • Contains 600 units of rapid-acting insulin compared with the 300 units in a U-100 pen1
  • Contains concentrated 200 U/mL insulin1
  • Delivers the same dose in half the liquid volume*1
  • Is the same size1 and familiar design as Humalog U-100 KwikPen
Learn more about Humalog U-200 KwikPen

*As compared with U-100 mealtime insulin pens.

Once opened, Humalog prefilled pens should be thrown away after 28 days, even if insulin remains.

As determined by area under the curve and maximum concentration.

Select Safety Information

Humalog, Humalog Mix75/25, and Humalog Mix50/50 are contraindicated during episodes of hypoglycemia and in patients who are hypersensitive to insulin lispro or any excipients contained in the formulation.

About Humalog® Mix75/25 (75% insulin lispro protamine suspension and 25% insulin lispro injection [rDNA origin])

Do you have a patient with type 2 diabetes who...

  • Needs greater glycemic control than oral medications alone are providing?3,4
  • Eats meals (often fast food) at about the same time every day?
  • Is willing to add insulin injections, but wants to minimize the number needed?
  • Is concerned about the cost of taking 2 insulins?
  • Wants to use a single product that will improve both mealtime and fasting control?3-5

Consider Humalog Mix75/25

  • A convenient premixed option combining 75% longer-acting insulin and 25% rapid-acting insulin
  • Is dosed 15 minutes prior to a meal
  • Provides both fasting and mealtime control in a single product3-5
  • Available in the Humalog® Mix75/25 KwikPen®
Learn more about Humalog Mix75/25 Learn more about the efficacy of Humalog Mix75/25

Select Safety Information

Never share a Humalog, Humalog Mix75/25, or Humalog Mix50/50 KwikPen, cartridge, reusable pen compatible with Lilly 3 mL cartridges, or syringe between patients as it poses a risk for transmission of blood-borne pathogens.

About Humalog® Mix50/50 (50% insulin lispro protamine suspension and 50% insulin lispro injection [rDNA origin])

Do you have a patient with type 2 diabetes who...

  • Needs more rapid-acting insulin to address postprandial glucose spikes?
  • Tends to eat carb-loaded meals, and tends to overeat?
  • Wants to use a pen device instead of vial and syringe?
  • Is concerned about the cost of an additional insulin?
  • Needs an insulin regimen that contains both a rapid-acting and longer-acting insulin?

Consider Humalog Mix50/50

  • 50% longer-acting insulin and 50% rapid-acting insulin
  • Is dosed 15 minutes prior to a meal
  • Improved mealtime control5-7
  • Provides patients the greatest amount of rapid-acting insulin of any commercially available premixed insulin
  • Available in the Humalog® Mix50/50 KwikPen®
Learn more about Humalog Mix50/50 Learn more about the efficacy of Humalog Mix50/50

Select Safety Information

The safety and effectiveness of Humalog Mix50/50 in patients less than 18 years of age have not been established.

Humalog KwikPen | For patients with type 1 and caregivers who want a portable device

Do you have a patient with type 1 diabetes who...

  • Needs rapid-acting insulin in addition to long-acting insulin?
  • Doesn’t want to attract attention to their disease?
  • Wants a choice in delivery options?

In-use Humalog KwikPen should be used at room temperature, below 86°F (30°C), and must be used within 28 days or be discarded, even if it still contains Humalog.

Humalog KwikPen may help patients fit mealtime insulin therapy into their lives.

Humalog KwikPen is kept outside the refrigerator after first use. Patients should be instructed to always carry an extra pen.

Learn more about Humalog Learn more about treatment for severe hypoglycemia Learn about HumaPen® LUXURA® HD and other delivery options

Help your newly diagnosed families managing type 1 diabetes on their journey

At their most vulnerable moments of diagnosis and insulin initiation, your families managing type 1 diabetes can rely on us for starter kits and online educational resources. They can find comfort and hope in the many initiatives developed collaboratively with Disney—from cookbooks to storybooks, and a special Disney character with type 1 diabetes named Coco. And we continue our commitment throughout their journey with ongoing efforts like our summer camps for kids, scholarships for college, and awards to celebrate significant milestones of living life with diabetes without limits.

Help your newly diagnosed families managing type 1 diabetes on their journey

We'd also like to share a short video that highlights our many support opportunities.

Watch now

Select Safety Information

Humalog has not been studied in children with type 1 diabetes less than 3 years of age or in children with type 2 diabetes. Safety and effectiveness of Humalog Mix75/25 and Humalog Mix50/50 in patients less than 18 years of age have not been established.

Why Humalog U-100 KwikPen might be right for your patients

Humalog KwikPen is a small, lightweight, prefilled insulin pen for patients with type 2 or type 1 diabetes who want a portable device. Humalog KwikPen is small, kept outside the refrigerator after first use, and can be taken just about anywhere. Patients can carry it in their purse, backpack, or pocket because it’s the size of a marker.

In-use Humalog KwikPen should be stored at room temperature, below 86°F (30°C). Humalog KwikPen must be used within 28 days or be discarded, even if it still contains Humalog. Humalog® Mix75/25 KwikPen® or Humalog® Mix50/50 KwikPen® should be discarded 10 days after first use, even if there is insulin left in the pen.

Prescribe Humalog U-200 KwikPen for your patients who could benefit from a pen that lasts longer between pen changes.* Learn more

Humalog U-100 KwikPen is easy-to-use, easy-to-inject8

  • Easy to set the dose8
  • Easy to see the numbers8
  • Easy to dial up and back down for dose correction8‡
  • Easy to dispense maximum dose of 60 units8‡
  • Allows patients or caregivers to discreetly deliver insulin

To help patients and their caregivers learn how to inject using Humalog KwikPen, please click to access the Humalog U-100 KwikPen Instructions for Use.

*As compared with U-100 mealtime insulin pens.

Once opened, Humalog prefilled pens should be thrown away after 28 days, even if insulin remains.

Humalog KwikPen Design Validation User Study included adult male and female participants with type 1 and type 2 diabetes. Of the total 150 study participants, 56 were insulin-naïve, 42 were currently administering insulin with a vial and syringe, and 52 were experienced insulin pen users.

Select Safety Information

Closely monitor blood glucose in all patients treated with insulin. Change insulin regimens cautiously.

Pen needles for use with Humalog KwikPen

Humalog KwikPen is suitable for use with Becton Dickinson (BD) needles (sold separately and may require a separate prescription). BD offers a comprehensive line of advanced protection products. For more information about BD pen needles, visit the BD Diabetes website for healthcare professionals.

Pens and needles are for single-patient use only and should not be shared, even in healthcare facilities, as infection or disease can be spread from one person to another.

Discard needle before storing pen. A new needle should be used for each injection.

Do not withdraw insulin from the pen using a syringe.

Questions and answers

Humalog U-100, Mix75/25, and Mix50/50 KwikPen questions and answers

Below is information that may help you address some of the questions that patients with type 2 or type 1 diabetes or their caregivers may have about using Humalog U-100 KwikPen, or patients with type 2 diabetes may have about using Humalog Mix75/25 KwikPen and Humalog Mix50/50 KwikPen.

Learn more about the Humalog U-200 Kwik Pen Instructions for Use.

Preparation

How do I prepare my Humalog Mix75/25 KwikPen or Humalog Mix50/50 KwikPen?

Advise patients that a pen containing premixed insulin should be cloudy. The pen must be gently rolled 10 times and inverted 10 times to completely mix the insulin. The insulin should then look evenly mixed.

Can I use the same needle more than once?

No. Let patients know they should use a new needle for each injection. This will help ensure sterility. If needles are reused, patients may get the wrong amount of insulin, a clogged needle, or a jammed pen.

What kind of pen needle can be used with Humalog KwikPen?

BD’s insulin pen needles are recommended for use with Humalog KwikPen. There are a variety of pen needles available. Work with each patient to determine the type and size of pen needle appropriate for them.

What should I do if I am not sure how much insulin remains in my cartridge?

Patients should be instructed to hold the pen with the needle end pointing down. The scale on the clear Cartridge Holder shows an estimate of the number of units remaining. These numbers should NOT be used for measuring an insulin dose.

Priming (also known as “preparing”)

Why should I prime my Humalog KwikPen to a stream before each dose?

Inform patients about the importance of priming:

  1. If patients do not prime, they may get too much or too little insulin
  2. It ensures that the pen is ready to dose
  3. It confirms that a stream of insulin comes out of the tip of the needle when the Dose Knob is pushed in
  4. It removes air that may collect in the needle or insulin cartridge during normal use

What should I do if I cannot completely push in the Dose Knob when priming my Humalog KwikPen?

If a patient cannot completely push in the Dose Knob, they should be instructed to:

  1. Attach a new needle
  2. Prime the pen

What should I do if I see an air bubble in the cartridge?

Patients will need to be advised to prime the pen. Remind patients that they should not store the pen with the needle attached, as this may cause air bubbles to collect in the insulin cartridge. A small air bubble will not affect their dose and they can continue to take their dose as usual.

Injecting

Why is it difficult to push the Dose Knob when I try to inject?

Let patients know this could be caused by the following:

  1. Their needle may be clogged. Have them try attaching a new needle. When they do this they may see insulin come out of the needle. Then they should prime (also known as “prepare”) the pen
  2. Pressing the Dose Knob quickly may make the Dose Knob harder to push. Pressing the Dose Knob more slowly may make it easier

Using a larger diameter needle will make it easier to push the Dose Knob during their injection. Patients should consult with you to determine which needle size is best for them. If the Dose Knob continues to be difficult to push after following the steps above, refer to the steps below under "What should I do if my Humalog KwikPen is jammed?"

What should I do if my Humalog KwikPen is jammed?

A pen may be jammed if it is difficult to inject a dose or dial a dose. To help patients clear the jam:

  1. Have them attach a new needle. When they do this they may see insulin come out of the needle. Then they should prime the pen
  2. After priming, patients should dial their dose and inject
  3. If the Dose Knob is still difficult to push, instruct patients to contact The Lilly Answers Center at 1-800-LillyRx (1-800-545-5979)

What does it mean if insulin is leaking from the needle after I finished injecting my dose?

Let patients know they may have removed the needle from the skin too quickly.

  1. Make sure patients see a "0" in the Dose Window to confirm they received the complete dose
  2. For the next dose, instruct them to push and hold the Dose Knob in and count to 5 slowly before removing the needle

What should I do if my dose is dialed and the Dose Knob is accidentally pushed in without a needle attached?

Instruct patients to do the following:

  1. Dial back to 0
  2. Attach a new needle. When they do this they may see insulin come out of the needle
  3. Prime the pen
  4. Dial their dose and inject

What should I do if I dial a wrong dose (too high or too low)?

Have patients turn the Dose Knob backward or forward to correct the dose before injecting.

What should I do if I see insulin leaking from the pen needle while dialing the dose or correcting the dose?

Tell patients not to inject the dose because they may not get their complete dose. Instruct them to dial the pen down to 0 and prime the pen again. They should then dial their dose and inject.

What should I do if my full dose cannot be dialed?

The pen will not allow patients to dial a dose greater than the number of insulin units remaining in the cartridge.

Tell patients not to attempt dialing past the number of units remaining in the cartridge. They may either:

  1. Inject the partial dose and then inject the remaining dose using a new pen or
  2. Inject the full dose with a new pen

Why can’t I dial the dose to use the small amount of insulin that remains in my cartridge?

Inform patients that the pen is designed to deliver at least 300 units of insulin. The pen design prevents the cartridge from being completely emptied because the small amount of insulin that remains in the cartridge cannot be delivered.

Storage and Disposal

What is important storage information I should know about Humalog KwikPen?

Advise patients of the following:

  • Pens that have not been opened should be stored in a refrigerator but not in a freezer. Do not use a pen if it has been frozen
  • Do not store the pen with the needle attached. If the needle remains attached, insulin may leak from the pen, insulin may dry inside the needle causing the needle to clog, or air bubbles may form inside the cartridge
  • The pen they are currently using should be kept at room temperature and away from heat and light
  • Keep the pen out of the reach of children

How long will my Humalog KwikPen last?

Tell patients that a Humalog KwikPen that has been opened should be discarded after 28 days, even if it still contains insulin. Humalog Mix75/25 KwikPen or Humalog Mix50/50 KwikPen should be discarded after 10 days, even if it still contains insulin. Unopened, refrigerated pens can be kept until the printed expiration date. Do not use after the expiration date.

What should I do with used needles?

Patients should be instructed to dispose of used needles in a puncture-resistant container or according to your instruction.

What should I do with used pens?

Patients should be advised to dispose of used pens according to your instruction and without needles attached.

Pens and needles are for single-patient use only and should not be shared, even in healthcare facilities, as infection or disease can be spread from one person to another.

Do not withdraw insulin from the pen using a syringe.

Nationwide, Humalog U-100 has better coverage* than other mealtime insulins and, for more insured patients, costs less†‡

Humalog U-100 is available at the lowest branded co-pay on more plans than other mealtime insulins. The out-of-pocket costs for each patient will depend on their insurance plan, but Humalog has better coverage in the majority of cases. 

Learn more about Humalog U-100 formulary coverage in your area

For additional resources and support, click here.

*“Better coverage” means more insured patients nationwide can get Humalog U-100 KwikPen and vials at the lowest brand co-pay or better without restriction compared to NovoLog® FlexPen® and vials, respectively.

“Costs less” means the average co-pay volume for Humalog ($26-$30) is lower than the average co-pay volume for NovoLog ($32-33). For some patients, the co-pay amounts may be the same. Based on data and analysis from IMS PayerTrak for October-December 2015.

Applies to Humalog U-100 KwikPen and vials; comparison compiled from Commercial, Medicare, Medicaid FFS, and Managed Medicaid formulary data accurate as of 10/2015. The underlying total number of insured patients used to conclude “better coverage” and “costs less” was developed by Decision Resources Group (DRG) based on DRG’s National Managed Care Census, DRG’s Employer Vantage product, data from the Centers for Medicare & Medicaid Services, data from state Medicaid offices, and data from other publicly available sources, with assumptions to account for dependents included under reported enrolled patients. Enrollment figures may not be representative of an individual physician’s patient population.

Additional Formulary Information

  • Source: Managed Markets Insight & Technology (MMIT), LLC as of 10/2015, and is subject to change without notice by a health plan or state. Please contact the plan or state for the most current information.
  • This information is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures.
  • The formulary information does not include generic medications in this therapeutic class.
  • Employers and employer groups may also offer additional benefit designs which may be different than described.
  • Co-payment amounts are subject to change by plans without notice. Lower co-payment cost alone does not necessarily reflect a cost advantage in the outcome of the condition treated because there may be other variables that affect relative costs.
  • The formulary information in this document is for select products that share an approved indication with Humalog U-100. Inclusion of a product in this chart does not establish clinical comparability of the products for any or all indications and should not be seen as making any claim regarding efficacy or safety.

References

  1. Anderson JH Jr, Brunelle RL, Keohane P, et al. Multicenter Insulin Lispro Study Group. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med. 1997;157(11):1249-1255.
  2. Humalog [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC; 2015.
  3. Malone JK, Kerr LF, Campaigne BN, et al. Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy [published correction appears in Clin Ther. 2005;27(7):1112]. Clin Ther. 2004;26(12):2034-2044.
  4. Malone JK, Bai S, Campaigne BN, et al. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med. 2005;22(4):374-381.
  5. Schwartz S, Zagar AJ, Althouse SK, Pinaire JA, Holcombe JH. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus. Clin Ther. 2006;28(10):1649-1657.
  6. Kazda C, Hülstrunk H, Helsberg K, Langer F, Forst T, Hanefeld M. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications. 2006;23:145-152.
  7. Roach P, Trautmann M, Arora V, Sun B, Anderson JH Jr. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Clinical Ther. 1999;23:523-534.
  8. Data on file, Lilly Research Laboratories: HUM20071024A.

Other product/company names and logos mentioned herein are the trademarks/property of their respective owners.